- 345 Downloads
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to human vascular endothelial growth factor and inhibits angiogenesis and hence tumour growth. It is available in the US and other countries for the treatment of several types of cancer, including glioblastoma that has recurred after previous treatment.
Two prospective phase II trials have evaluated bevacizumab 10mg/kg every 2 weeks for the treatment of previously treated glioblastoma. In the randomized, noncomparative, multicentre AVF3708g trial in patients with glioblastoma in first or second relapse, the rate of progression-free survival at 6 months was 42.6% and the objective response rate was 28.2% in recipients of bevacizumab alone (n = 85). In the bevacizumab plus irinotecan treatment arm (n=82), the 6-month progression-free survival rate was 50.3% and the objective response rate was 37.8%. These rates were all significantly higher than historical control data.
In the supporting, single-arm, single-centre, phase II NCI 06-C-0064E trial of bevacizumab in patients with glioblastoma that had recurred after radiotherapy and temozolomide chemotherapy (n = 48), the rate of progression-free survival at 6 months was 29% and the overall response rate based on Macdonald criteria was 35%.
Given the nature of the disease, bevacizumab was generally well tolerated in these two phase II trials. In the AVF3708g trial, grade 3 or higher treatment-emergent adverse events occurred in 46.4% of bevacizumab and 65.8% of bevacizumab plus irinotecan recipients.
KeywordsVascular Endothelial Growth Factor Bevacizumab Irinotecan Objective Response Rate Karnofsky Performance Status
Acknowledgements and Disclosures
The manuscript was reviewed by: H.S. Friedman, Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA; T.N. Kreisl, Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA; P.Y. Wen, Center for Neuro-Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Boston, Massachusetts, USA.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
- 2.Central Brain Tumor Registry of the United States (CBTRUS). Statistical report: primary brain tumors in the United States, 2007–2008 (years of data collected 2000–2004) [online]. Available from URL: http://www.cbtrus.org/reports//2007-2008/2007report.pdf [Accessed 2009 Sep 14]
- 3.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers V.2.2009 [online]. Available from URL: http://www.nccn.org [Accessed 2009 Sep 14]
- 8.Avastin® (bevacizumab) solution for intravenous infusion: US prescribing information. South San Francisco (CA): Genentech, Inc., 2009 JulGoogle Scholar
- 22.Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001 Feb 1; 19(3): 851–6PubMedGoogle Scholar
- 24.Mahmood I. Center for Drug Evaluation and Research. Approval package for application number STN-125085/0: clinical pharmacology/TOX review [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/STN-125085_Avastin_BioPharmr.pdf [Accessed 2009 Sep3]
- 27.US Food and Drug Administration. FDA briefing document: Oncology Drug Advisory Committee meeting; March 31, 2009; BLA STN 125085/169 Avastin® (bevacizumab) [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4427b1-01-FDA.pdf [Accessed 2009 Aug 12]
- 31.Wefel JS, Cloughesy T, Zazzali J, et al. Neurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN study [abstract no. 2056]. J Clin Oncol 2009; 27 Suppl.: 15s. Plus poster presented at the 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29–Jun 2; Orlando (FL)CrossRefGoogle Scholar